Vaxart, Inc. (VXRT) Stock: Is This Biotechnology Stock Worth Your Consideration?

0
107

Vaxart, Inc. (VXRT) is trending up in the market today. The stock, one that is focused on the biotechnology space, is currently priced at $0.72 after heading up 7.02% so far in today’s session. When it comes to biotechnology stocks, there are quite a few factors that have the potential to cause gains in the market. News is one of the most common reasons for movement. Here are the recent trending headlines relating to VXRT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-29-19 08:00AM New Publication in Vaccine Highlights Preclinical Results of Vaxarts Mucosal Chikungunya Vaccine
May-09-19 04:01PM Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
May-07-19 01:41PM Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
Apr-16-19 04:01PM Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Apr-12-19 08:00AM Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases

Nonetheless, when making an investing decision, investors should look into far more than just news, especially in the speculative biotech industry. Here’s what’s happening with Vaxart, Inc..

Performance Trends That We’ve Seen From VXRT

Although a move toward the top in a single session, like what we’re seeing from Vaxart, Inc. might lead to excitement in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always important to take a look at trends experienced by the stock beyond a single session. As it relates to VXRT, below are the returns on investment that investors have experienced:

  • Past 5 Trading Sessions – Over the past 7 days, VXRT has produced a price change amounting to 12.89%.
  • Monthly – The ROI from Vaxart, Inc. throughout the past 30 days has been -6.49%.
  • Quarterly – In the last quarter, the stock has produced a return that works out to -58.86%
  • Past Six Months – Throughout the previous six months, we have seen a change that amounts to -76.00% from the company.
  • This Year So Far – Since the open of this year VXRT has produced a ROI of -61.70%.
  • Full Year – Lastly, in the last year, investors have seen movement amounting to -79.37% out of VXRT. Throughout this period of time, the stock has sold at a high of -90.53% and a low price of 19.03%.

Key Ratios

Digging into various ratios having to do with a stock generally gives investors an understanding of how dangerous and/or rewarding a an investment option may be. Below are some of the important ratios to consider when digging into VXRT.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. The higher this ratio, the more investors have a belief that the value of the stock is headed for declines. In general, biotech stocks can carry a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the space. Nonetheless, as it relates to Vaxart, Inc., the stock’s short ratio comes to 0.38.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to cover its debts as they mature using quick assets or current assets. Because many biotech several companies rely heavily on the continuation of support from investors, the quick and current ratios can seem damning. Nonetheless, several better companies in the biotech industry come with strong quick and current ratios. When it comes to VXRT, the quick and current ratios add up to 1.80 and 1.80 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price. when it comes to Vaxart, Inc., the book to share value ratio works out to 1.72.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is an important ratio to consider. When it comes to VXRT, the cash to share value comes to 0.

Analyst Opinions With Regard To Vaxart, Inc.

Although it’s never a good idea to blindly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own due diligence before making an investment decision in the biotech sector. Below are the recent moves that we’ve seen from analysts with regard to VXRT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Smart Money Follows Big Money

One thing I have come to understand so far in my brief time on Earth has been that smart money tends to follow the moves made by big money players. In other words, investors that are trying to keep the risk down will follow trades made by institutional investors and those on the inside. With that said, where is the big money in regard to VXRT? Here’s what’s happening:

Institutions own 25.10% of the company. Institutional interest has moved by 6.40% over the past three months. When it comes to insiders, those who are close to the company currently own 3.20% percent of VXRT shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s Going On With Share Counts?

Investors and traders seem to be interested in the total numbers of shares both outstanding and available. With respect to Vaxart, Inc., there are currently 15.23M and there is a float of 12.42M. These numbers mean that of the total of 15.23M shares of VXRT currently in existence today, 12.42M are available to be traded on the public market.

I also like to look at the short percent. After all, when a large portion of the float available for trading is shorted, the overall opinion in the market is that the stock is headed for a steep decline. With regard to VXRT, the short percentage of the float is currently 3.33%. In general, concerning short percent of the float would be considered to be anything over 40%. In my research, I have calculated that a short percent of the float over 26% is generally a play that comes with hefty risk.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, VXRT has generated revenue in the amount of $-42.90% with earnings coming in at 5.50%. On a quarter over quarter basis, earnings have seen movement of -149.20% and revenue has seen movement of 260.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was developed by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you would to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at data? If so, write a comment below and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here